Soligenix Inc. Reports Promising Phase 3 Progress for HyBryte(TM) in CTCL Treatment
Soligenix Inc. shares encouraging interim results from its phase 3 trial of HyBryte(TM) for cutaneous T-cell lymphoma, highlighting potential advancements in treatment options for this rare disease.
During a recent investment webinar, Soligenix Inc. (NASDAQ: SNGX) provided updates on the clinical development of HyBryte(TM), its synthetic hypericin treatment for cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma. The webinar highlighted interim results from an investigator-initiated study at the University of Pennsylvania, showing that 75% of the first eight patients who completed 18 weeks of treatment experienced a greater than 50% reduction in disease severity. Soligenix anticipates releasing top-line results from its confirmatory phase 3 trial in the second half of 2026.
HyBryte(TM), a topical therapy activated by visible light, targets early-stage mycosis fungoides, which constitutes nearly 90% of CTCL cases. The treatment represents a significant step forward in addressing the unmet medical needs of patients with this rare disease. Dr. Christopher Schaber, Soligenix's chairman, president, and CEO, emphasized the potential of HyBryte(TM) to transform the treatment landscape for CTCL. Further details on the clinical development can be found here.
Soligenix's commitment to developing innovative treatments for rare diseases is underscored by the progress of HyBryte(TM). The company's efforts could offer new hope to patients suffering from CTCL, a condition with limited treatment options. The upcoming phase 3 trial results will be crucial in determining the therapy's efficacy and potential for regulatory approval.